Skip to main content
main-content

01.09.2009 | Original article | Ausgabe 9/2009

Netherlands Heart Journal 9/2009

Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism

Zeitschrift:
Netherlands Heart Journal > Ausgabe 9/2009
Autoren:
M. G. J. Duffels, M. N. van der Plas, S. Surie, M. M. Winter, B. J. Bouma, M. Groenink, A. P. J. van Dijk, E. S. Hoendermis, R. M. F. Berger, P. Bresser, B. J. M. Mulder
Wichtige Hinweise
Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands
Department of Pulmonology, Academic Medical Center, Amsterdam, the Netherlands
Department of Cardiology, University Medical Center Nijmegen, the Netherlands
Department of Cardiology, University Medical Center Groningen, the Netherlands
Department of Paediatric Cardiology University Medical Center Groningen, the Netherlands
Departments of Cardiology, Academic Medical Center, Amsterdam and University Medical Center Utrecht, Utrecht, the Netherlands
B.J.M. Mulder Department of Cardiology, Rm B2–240, Academic Medical Center, PO Box 22660, 1100 DD Amsterdam, the Netherlands

Abstract

Background. In patients with pulmonary hypertension, it is unknown whether the treatment effect of bosentan is dependent on the duration of pulmonary vessel changes. Therefore, we studied the response to bosentan in patients with life-long pulmonary vessel changes (pulmonary arterial hypertension (PAH) due to congenital heart disease (CHD)) and in patients with subacutely induced pulmonary vessel changes (chronic thromboembolic pulmonary hypertension (CTEPH)).
Methods. In this open-label study, 18 patients with PAH due to CHD and 16 patients with CTEPH were treated with bosentan for at least one year. All patients were evaluated at baseline and during follow-up by means of the six-minute walk distance (6-MWD) and laboratory tests.
Results. Improvement of 6-MWD was comparable in patients with PAH due to CHD (444±112 m to 471±100 m, p=0.02), and in CTEPH (376±152 m to 423±141 m, p=0.03) after three months of treatment. After this improvement, 6-MWD stabilised in both groups.
Conclusion. Although duration of pulmonary vessel changes is strikingly different in patients with PAH due to CHD and CTEPH, the effect of one year of bosentan treatment was comparable. The main treatment effect appears to be disease stabilisation and decreasing the rate of deterioration. (Neth Heart J 2009;17:334–8.)

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2009

Netherlands Heart Journal 9/2009Zur Ausgabe

Interuniversity Cardiology Institute of the Netherlands

Cardiac resynchronisation therapy and the role of optimal device utilisation

Neu im Fachgebiet Kardiologie

 

 

 
 

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise